HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $157 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Ligand Pharmaceuticals, maintaining a price target of $157.
October 31, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Ligand Pharmaceuticals, maintaining a price target of $157.
The reiteration of a Buy rating and maintenance of a $157 price target by HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Ligand Pharmaceuticals' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100